Payment overview · 2025
General Payments
$81.43
5 reported records · 5 companies
Healthcare provider profile · identity verified
Patrick J Mccarville, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · VALLEY, NE · NPI 1891803698
Verified facts
What the public records show
CMS Open Payments records show Patrick J Mccarville, M.D. received $81.43 in general payments during 2025 across 5 reported records.
Astellas Pharma US Inc accounted for 24.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Myrbetriq by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 255 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $19.51 | 24.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.53 | 20.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.11 | 19.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.82 | 19.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.46 | 16.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $81.43 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $19.51 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.11 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $16.11 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.11 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $16.11 | 1 | 2025 |
Source payment records
|
|||||
| PROQUAD Normalized: proquad |
Biological | Merck Sharp & Dohme LLC | $16.11 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $13.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 255 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
255 | 36 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 644 | 164 |
| Levothyroxine Sodium | Levothyroxine Sodium | 419 | 94 |
| Losartan Potassium | Losartan Potassium | 364 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 322 | 77 |
| Furosemide | Furosemide | 267 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 263 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 260 | 72 |
| Eliquis | Apixaban | 255 | 36 |
| Carvedilol | Carvedilol | 241 | 56 |
| Simvastatin | Simvastatin | 229 | 50 |
| Metformin Hcl Er | Metformin Hcl | 218 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 186 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 172 | 49 |
| Lisinopril | Lisinopril | 151 | 38 |
| Metformin Hcl | Metformin Hcl | 151 | 40 |
| Gabapentin | Gabapentin | 147 | 36 |
| Omeprazole | Omeprazole | 145 | 39 |
| Potassium Chloride | Potassium Chloride | 136 | 27 |
| Tramadol Hcl | Tramadol Hcl | 136 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 125 | 28 |
| Trazodone Hcl | Trazodone Hcl | 122 | 29 |
| Jardiance | Empagliflozin | 116 | 30 |
| Alprazolam | Alprazolam | 113 | 24 |
| Sertraline Hcl | Sertraline Hcl | 113 | 27 |
| Spironolactone | Spironolactone | 105 | 27 |
| Prednisone | Prednisone | 103 | 53 |
| Benazepril Hcl | Benazepril Hcl | 100 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 99 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 95 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 95 | 22 |
| Allopurinol | Allopurinol | 94 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 94 | 21 |
| Finasteride | Finasteride | 93 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 89 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 82 | 15 |
| Glimepiride | Glimepiride | 81 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 81 | 13 |
| Famotidine | Famotidine | 77 | 28 |
| Doxycycline Hyclate | Doxycycline Hyclate | 72 | 54 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 71 | 23 |
| Ezetimibe | Ezetimibe | 71 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 71 | 18 |
| Mirtazapine | Mirtazapine | 63 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | 11 |
| Myrbetriq | Mirabegron | 59 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 58 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 15 |
| Montelukast Sodium | Montelukast Sodium | 53 | 14 |
| Xarelto | Rivaroxaban | 53 | suppressed |
| Meloxicam | Meloxicam | 52 | 17 |
| Ozempic | Semaglutide | 50 | suppressed |
| Synthroid | Levothyroxine Sodium | 50 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 49 | suppressed |
| Baclofen | Baclofen | 45 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Clonazepam | Clonazepam | 44 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 43 | suppressed |
| Torsemide | Torsemide | 42 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 42 | suppressed |
| Atenolol | Atenolol | 41 | suppressed |
| Lorazepam | Lorazepam | 41 | suppressed |
| Levetiracetam | Levetiracetam | 39 | suppressed |
| Nystatin | Nystatin | 39 | 14 |
| Clonidine Hcl | Clonidine Hcl | 37 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 35 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 34 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Levemir Flexpen | Insulin Detemir | 32 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| M-Natal Plus | Pnv,calcium 72/Iron/Folic Acid | 30 | suppressed |
| Diazepam | Diazepam | 29 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Brilinta | Ticagrelor | 28 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Humulin R | Insulin Regular, Human | 20 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Azithromycin | Azithromycin | 18 | 17 |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | 11 |
| Latanoprost | Latanoprost | 18 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Cefdinir | Cefdinir | 16 | 15 |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 15 | suppressed |
| Fluorouracil | Fluorouracil | 15 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 14 |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Copaxone | Glatiramer Acetate | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 13 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Letrozole | Letrozole | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 13 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Felbamate | Felbamate | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 12 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $81.43 · 5 records | Astellas Pharma US Inc | CAPVAXIVE, ELIQUIS, ENFLONSIA, GARDASIL 9, M-M-R II, NURTEC ODT, PROQUAD, REXULTI, The Cologuard Plus Collection Kit, Veozah | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error